Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00876070

Enrollment

198

Registered

2009-04-06

Start date

2008-11-30

Completion date

2011-02-28

Last updated

2011-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Breast Cancer

Keywords

Metastatic Breast Cancer, Breast Cancer, MBC, Abraxane, Paclitaxel, Taxol, Docetaxel, Taxotere

Brief summary

This is a retrospective medical record abstraction study. It is a review and evaluation of up to 300 metastatic breast cancer patients treated with Abraxane or other taxanes such as paclitaxel and docetaxel to determine the overall cost of care for Abraxane compared to other taxanes in the first-line metastatic cancer setting and the cost of care for Abraxane compared to other taxanes when broken down by individual components of cost. In addition, the investigators will review the following patient outcomes: response rate, duration of therapy, toxicity, and survival.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients that have received Abraxane chemotherapy greater than three months from the time of chart review. * Patients that have received taxane chemotherapy greater than three months from the time of chart review.

Design outcomes

Primary

Measure	Time frame
Describe patient demographics, disease and treatment characteristics.	6 months

Secondary

Measure	Time frame
Describe detailed treatment and response characteristics.	6 months
Describe resource utilization and cost variables.	6 months

Countries

United States

Outcome results